Opko subsidiary Bio-Reference Laboratories is retiring GeneTests.org next month given the availability of the NIH-backed Genetic Testing Registry.
The alliance will combine the two firms' technologies and know-how to provide doctors with insights into patients' health status.
Under today's deal, all of UC Health's medical centers will work with GeneDx and have access to more than 400 of the firm's tests for rare hereditary disorders.
Diaceutics will use the data to help its pharmaceutical industry clients speed their rollouts of new cancer drugs.
Going forward, Natera said it will market its Panorama NIPT assay and carrier screening test Horizon directly to physicians.
Around 16,000 4Kscore prostate cancer tests were performed in Q3, which is a 365 percent increase over Q3 2015.
Experts said that the EMR is a crucial channel for aggregating clinical insights from multiple sources, but plenty of work is needed to achieve broader adoption.
The company, which is part of Opko Health's BioReference Laboratories, recently hired a new managing director, who plans to expand the firm's market and testing portfolio.
The two entities also plan to work together using the data generated from the tests to do added research.
The performance of WES for genetically heterogeneous disorders improves significantly when testing is performed on the proband and two or more family members.
Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.
The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.
CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.
In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.